Efficacy of avelumab and axitinib depending on disease burden in patients with metastatic renal cell carcinoma: a subgroup analysis of the RAVE-Renal trial

Background. Immunotherapies and targeted therapies have demonstrated significant efficacy in prospective randomized trials establishing them as the standard of care for patients with metastatic renal cell carcinoma.

This analysis, part of the RAVE-Renal real-world study, aimed to evaluate the effectiveness of avelumab plus axitinib based on disease burden and the presence of liver and bone metastases.

Materials and methods. The RAVE-Renal trial was a multicenter, ambispective study that included treatment-naïve patients with histologically confirmed metastatic renal cell carcinoma and measurable lesions. Patients were treated with avelumab (800 mg every two weeks) and axitinib (5 mg twice daily). Primary endpoints were median progressionfree survival (PFS) and objective response rate (ORR). Secondary endpoints included median overall survival, 1-year overall survival, and safety. Subgroup analyses evaluated median PFS and ORR in patients with ³2 organ metastases, bone metastases, and liver metastases.

Results. A total of 125 patients from 13 centers were enrolled, with median follow-up of 16.1 months and median age of 61 years. Based on IMDC (International Metastatic RCC Database Consortium) risk categories, 35.3 % had favorable, 49 % had intermediate, and 15.7 % had poor prognosis. The overall population demonstrated median PFS of 14.9 months and ORR of 44.3 %. Among patients with ³2 organ metastases, median PFS was 13.0 months, and ORR was 36.7 % (all p >0.05). In those with bone metastases, median PFS was 6.5 months (p = 0.160), and ORR was 23.5 % (p = 0.0148). For patients with liver metastases, median PFS was 17.6 months, and ORR was 45.5 % (all p >0.05).

Conclusion. The combination of avelumab and axitinib demonstrated consistent efficacy in patients with advanced disease including those with liver and bone metastases. These findings suggest the regimen’s broad applicability and suitability in real-world clinical practice.

1. Tsimafeyeu I., Rahib L. The future landscape of cancer incidence and mortality until 2036 in the Russian Federation. J Clin Oncol 2022;40(16_suppl):e22518. DOI: 10.1200/JCO.2022.40.16_suppl.e22518

2. Tsimafeyeu I., Shatkovskaya O., Krasny S. et al. Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry. Cancer Rep (Hoboken) 2021;4(3):e1331. DOI: 10.1002/cnr2.1331

3. Tomita Y., Motzer R.J., Choueiri T.K. et al. Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101. ESMO Open 2023;8(6):102034. DOI: 10.1016/j.esmoop.2023.102034

4. Tsimafeyeu I. Sunitinib in patients with metastatic renal cell carcinoma with favorable risk: be aware of PD-L1 expression. Med Sci (Basel) 2024;12(3):48. DOI: 10.3390/medsci12030048

5. https://www.merckgroup.com/ru-ru/news/pr-01-09-2021.html

6. Tsimafeyeu I., Chubenko V., Baklanova O. et al. Real-world efficacy and safety of avelumab plus axitinib in metastatic renal cell carcinoma: results from the ambispective RAVE-Renal study. Curr Oncol 2025;32(1):11. DOI: 10.3390/curroncol32010011

7. Chubenko V., Baklanova O., Kalpinskiy A. et al. Avelumab plus axitinib for first-line treatment of advanced renal cell carcinoma: a real-world ambispective RAVE-Renal study. J Clin Oncol 2024;42:117.

8. Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271–81. DOI: 10.1056/NEJMoa066838

9. Roviello G., Molina-Cerrillo J., Massari F. et al. First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study. Cancer Immunol Immunother 2025;74(2):65. DOI: 10.1007/s00262-024-03897-x

10. Dengina N., Mitin T., Gamayunov S. et al. Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicenter study. ESMO Open 2019;4(5):e000535. DOI: 10.1136/esmoopen-2019-000535

11. Liu X., Zhou Q., Xu Y. et al. Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed? Oncotarget 2017;8(49):86969–84. DOI: 10.18632/oncotarget.21160

12. Jammihal T., Saliby R.M., Labaki C. et al. Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma. Nat Cancer 2025;6(2):372–84. DOI: 10.1038/s43018-024-00896-w

13. Gerlinger M., Rowan A.J., Horswell S. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366(10):883–92. Erratum in: N Engl J Med 2012;367(10):976. DOI: 10.1056/NEJMoa1113205

14. Crusz S.M., Tang Y.Z., Sarker S.J. et al. Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma. BMC Med 2016;14(1):185. DOI: 10.1186/s12916-016-0729-9

15. Tsimafeyeu I., Makhov P., Ovcharenko D. et al. A novel antiFGFR1 monoclonal antibody OM-RCA-01 exhibits potent antitumor activity and enhances the efficacy of immune checkpoint inhibitors in lung cancer models. Immunooncol Technol 2024;23:100725. DOI: 10.1016/j.iotech.2024.100725

16. Heidegger I., Pircher A., Pichler R. Targeting the tumor microenvironment in renal cell cancer biology and therapy. Front Oncol 2019;9:490. DOI: 10.3389/fonc.2019.00490

17. Nathan P.D., Charnley N., Frazer R. et al. A UK real-world observational study of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): outcomes at 36 months post treatment initiation. J Clin Oncol 2024;42:386.

18. Kato T., Nakano Y., Hongo F. et al. Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART). Int J Urol 2024;31(3):265–72. DOI: 10.1111/iju.15345

19. Motzer R.J., Penkov K., Uemura K. et al. Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial. J Clin Oncol 2024;42:4508. DOI: 10.1200/JCO.2024.42.16_suppl.4508

20. Grünwald V., McKay R.R., Buchler T. et al. Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: post hoc analysis of the CLEAR trial. Int J Cancer 2025;156(7):1326–35. DOI: 10.1002/ijc.35288

21. Tsimafeyeu I.V., Baklanova O.V., Chubenko V.A., et al. Avelumab in combination with axitinib and nivolumab in combination with ipilimumab in the first-line treatment of metastatic renal cell carcinoma: a real world retrospective cohort study. Zlokachestvennye opukholi = Malignant Tumors 2024;14(4):9–17. (In Russ.). DOI: 10.18027/2224-5057-2024-032